Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 62

1.

Versatility of the adenovirus-vectored foot-and-mouth disease vaccine platform across multiple foot-and-mouth disease virus serotypes and topotypes using a vaccine dose representative of the AdtA24 conditionally licensed vaccine.

Barrera J, Brake DA, Schutta C, Ettyreddy D, Kamicker BJ, Rasmussen MV, Bravo de Rueda C, Zurita M, Pisano M, Hurtle W, Brough DE, Butman BT, Harper BG, Neilan JG.

Vaccine. 2018 Nov 19;36(48):7345-7352. doi: 10.1016/j.vaccine.2018.10.031. Epub 2018 Oct 13.

2.

Efficacy of an adenovirus-vectored foot-and-mouth disease virus serotype A subunit vaccine in cattle using a direct contact transmission model.

Neilan JG, Schutta C, Barrera J, Pisano M, Zsak L, Hartwig E, Rasmussen MV, Kamicker BJ, Ettyreddy D, Brough DE, Butman BT, Brake DA.

BMC Vet Res. 2018 Aug 29;14(1):254. doi: 10.1186/s12917-018-1582-1.

3.

Use of ENABL® adjuvant to increase the potency of an adenovirus-vectored foot-and-mouth disease virus serotype A subunit vaccine.

Barrera J, Schutta C, Pisano M, Grubman MJ, Brake DA, Miller T, Kamicker BJ, Olutunmbi F, Ettyreddy D, Brough DE, Butman BT, Neilan JG.

Vaccine. 2018 Feb 14;36(8):1078-1084. doi: 10.1016/j.vaccine.2018.01.026. Epub 2018 Jan 20.

4.

Safety profile of a replication-deficient human adenovirus-vectored foot-and-mouth disease virus serotype A24 subunit vaccine in cattle.

Barrera J, Brake DA, Kamicker BJ, Purcell C, Kaptur R Jr, Schieber T, Lechtenberg K, Miller TD, Ettyreddy D, Brough DE, Butman BT, Colby M, Neilan JG.

Transbound Emerg Dis. 2018 Apr;65(2):447-455. doi: 10.1111/tbed.12724. Epub 2017 Oct 27.

5.

Profiling the Targets of Protective CD8+ T Cell Responses to Infection.

Bruder JT, Chen P, Ekberg G, Smith EC, Lazarski CA, Myers BA, Bolton J, Sedegah M, Villasante E, Richie TL, King CR, Aguiar JC, Doolan DL, Brough DE.

Mol Ther Methods Clin Dev. 2017 Aug 18;7:20-31. doi: 10.1016/j.omtm.2017.08.003. eCollection 2017 Dec 15.

6.

New gorilla adenovirus vaccine vectors induce potent immune responses and protection in a mouse malaria model.

Limbach K, Stefaniak M, Chen P, Patterson NB, Liao G, Weng S, Krepkiy S, Ekberg G, Torano H, Ettyreddy D, Gowda K, Sonawane S, Belmonte A, Abot E, Sedegah M, Hollingdale MR, Moormann A, Vulule J, Villasante E, Richie TL, Brough DE, Bruder JT.

Malar J. 2017 Jul 3;16(1):263. doi: 10.1186/s12936-017-1911-z.

7.

Multiple efficacy studies of an adenovirus-vectored foot-and-mouth disease virus serotype A24 subunit vaccine in cattle using homologous challenge.

Schutta C, Barrera J, Pisano M, Zsak L, Grubman MJ, Mayr GA, Moraes MP, Kamicker BJ, Brake DA, Ettyreddy D, Brough DE, Butman BT, Neilan JG.

Vaccine. 2016 Jun 8;34(27):3214-3220. doi: 10.1016/j.vaccine.2015.12.018. Epub 2015 Dec 18.

8.

Ocular localization and transduction by adenoviral vectors are serotype-dependent and can be modified by inclusion of RGD fiber modifications.

Ueyama K, Mori K, Shoji T, Omata H, Gehlbach PL, Brough DE, Wei LL, Yoneya S.

PLoS One. 2014 Sep 18;9(9):e108071. doi: 10.1371/journal.pone.0108071. eCollection 2014.

9.

Optimizing atoh1-induced vestibular hair cell regeneration.

Staecker H, Schlecker C, Kraft S, Praetorius M, Hsu C, Brough DE.

Laryngoscope. 2014 Oct;124 Suppl 5:S1-S12. doi: 10.1002/lary.24775. Epub 2014 Jun 17.

10.

Therapeutic potential of adenovirus-mediated delivery of ╬▓-defensin 2 for experimental otitis media.

Woo JI, Kil SH, Brough DE, Lee YJ, Lim DJ, Moon SK.

Innate Immun. 2015 Feb;21(2):215-24. doi: 10.1177/1753425914534002. Epub 2014 May 19.

PMID:
24842664
11.

Identification of a suppressor mutation that improves the yields of hexon-modified adenovirus vectors.

Bruder JT, Chen P, Semenova E, Thomas CA, Konovalova S, Ekberg G, Ettyreddy D, McVey D, Gall JG, King CR, Brough DE.

J Virol. 2013 Sep;87(17):9661-71. doi: 10.1128/JVI.00462-13. Epub 2013 Jul 3.

12.

Adenoviruses isolated from wild gorillas are closely related to human species C viruses.

Duncan M, Cranfield MR, Torano H, Kuete HM, Lee GP, Glenn A, Bruder JT, Rangel D, Brough DE, Gall JG.

Virology. 2013 Sep;444(1-2):119-23. doi: 10.1016/j.virol.2013.05.041. Epub 2013 Jun 24.

13.

Genetic vaccine for respiratory syncytial virus provides protection without disease potentiation.

Johnson TR, Rangel D, Graham BS, Brough DE, Gall JG.

Mol Ther. 2014 Jan;22(1):196-205. doi: 10.1038/mt.2013.142. Epub 2013 Jun 10.

14.

Canalostomy as a surgical approach for cochlear gene therapy in the rat.

Gassner D, Durham D, Pfannenstiel SC, Brough DE, Staecker H.

Anat Rec (Hoboken). 2012 Nov;295(11):1830-6. doi: 10.1002/ar.22593. Epub 2012 Oct 8.

15.

Human adenovirus-vectored foot-and-mouth disease vaccines: establishment of a vaccine product profile through in vitro testing.

Brake DA, McIlhaney M, Miller T, Christianson K, Keene A, Lohnas G, Purcell C, Neilan J, Schutta C, Barrera J, Burrage T, Brough DE, Butman BT.

Dev Biol (Basel). 2012;134:123-33.

PMID:
22888605
16.

The presence of alpha interferon at the time of infection alters the innate and adaptive immune responses to porcine reproductive and respiratory syndrome virus.

Brockmeier SL, Loving CL, Nelson EA, Miller LC, Nicholson TL, Register KB, Grubman MJ, Brough DE, Kehrli ME Jr.

Clin Vaccine Immunol. 2012 Apr;19(4):508-14. doi: 10.1128/CVI.05490-11. Epub 2012 Feb 1.

17.

Atoh1 induces auditory hair cell recovery in mice after ototoxic injury.

Kraft S, Hsu C, Brough DE, Staecker H.

Laryngoscope. 2013 Apr;123(4):992-9. doi: 10.1002/lary.22171. Epub 2013 Mar 11.

18.

Selective atonal gene delivery improves balance function in a mouse model of vestibular disease.

Schlecker C, Praetorius M, Brough DE, Presler RG Jr, Hsu C, Plinkert PK, Staecker H.

Gene Ther. 2011 Sep;18(9):884-90. doi: 10.1038/gt.2011.33. Epub 2011 Apr 7.

19.

Development of gene therapy for inner ear disease: Using bilateral vestibular hypofunction as a vehicle for translational research.

Staecker H, Praetorius M, Brough DE.

Hear Res. 2011 Jun;276(1-2):44-51. doi: 10.1016/j.heares.2011.01.006. Epub 2011 Jan 18. Review.

20.

Characterization of human adenovirus 35 and derivation of complex vectors.

McVey D, Zuber M, Ettyreddy D, Reiter CD, Brough DE, Nabel GJ, King CR, Gall JG.

Virol J. 2010 Oct 19;7:276. doi: 10.1186/1743-422X-7-276.

21.

Adenovector-mediated hair cell regeneration is affected by promoter type.

Praetorius M, Hsu C, Baker K, Brough DE, Plinkert P, Staecker H.

Acta Otolaryngol. 2010 Feb;130(2):215-22. doi: 10.3109/00016480903019251.

22.

Repair of the vestibular system via adenovector delivery of Atoh1: a potential treatment for balance disorders.

Baker K, Brough DE, Staecker H.

Adv Otorhinolaryngol. 2009;66:52-63. doi: 10.1159/000218207. Epub 2009 Jun 2. Review.

PMID:
19494572
23.

Adenovirus-mediated expression of interferon-alpha delays viral replication and reduces disease signs in swine challenged with porcine reproductive and respiratory syndrome virus.

Brockmeier SL, Lager KM, Grubman MJ, Brough DE, Ettyreddy D, Sacco RE, Gauger PC, Loving CL, Vorwald AC, Kehrli ME Jr, Lehmkuhl HD.

Viral Immunol. 2009 Jun;22(3):173-80. doi: 10.1089/vim.2008.0075.

PMID:
19435413
24.

Replication-defective adenovirus vectors with multiple deletions do not induce measurable vector-specific T cells in human trials.

Koup RA, Lamoreaux L, Zarkowsky D, Bailer RT, King CR, Gall JG, Brough DE, Graham BS, Roederer M.

J Virol. 2009 Jun;83(12):6318-22. doi: 10.1128/JVI.00384-09. Epub 2009 Apr 1.

25.

Bcl-2 gene therapy prevents aminoglycoside-induced degeneration of auditory and vestibular hair cells.

Pfannenstiel SC, Praetorius M, Plinkert PK, Brough DE, Staecker H.

Audiol Neurootol. 2009;14(4):254-66. doi: 10.1159/000192953. Epub 2009 Jan 19.

PMID:
19151550
26.

Alternate serotype adenovector provides long-term therapeutic gene expression in the eye.

Hamilton MM, Byrnes GA, Gall JG, Brough DE, King CR, Wei LL.

Mol Vis. 2008;14:2535-46. Epub 2008 Dec 30.

27.

Adenoviral vectors for improved gene delivery to the inner ear.

Praetorius M, Brough DE, Hsu C, Plinkert PK, Pfannenstiel SC, Staecker H.

Hear Res. 2009 Feb;248(1-2):31-8. doi: 10.1016/j.heares.2008.11.009. Epub 2008 Dec 7.

28.

Persistent expression of PEDF in the eye using high-capacity adenovectors.

Chen P, Hamilton M, Thomas CA, Kroeger K, Carrion M, Macgill RS, Gehlbach P, Brough DE, Wei LL, King CR, Bruder JT.

Mol Ther. 2008 Dec;16(12):1986-94. doi: 10.1038/mt.2008.211. Epub 2008 Sep 30.

29.

Repeat administration of proteins to the eye with a single intraocular injection of an adenovirus vector.

McVey D, Hamilton MM, Hsu C, King CR, Brough DE, Wei LL.

Mol Ther. 2008 Aug;16(8):1444-9. doi: 10.1038/mt.2008.124. Epub 2008 Jun 10.

30.

Rescue and production of vaccine and therapeutic adenovirus vectors expressing inhibitory transgenes.

Gall JG, Lizonova A, EttyReddy D, McVey D, Zuber M, Kovesdi I, Aughtman B, King CR, Brough DE.

Mol Biotechnol. 2007 Mar;35(3):263-73.

PMID:
17652790
31.

Vestibular hair cell regeneration and restoration of balance function induced by math1 gene transfer.

Staecker H, Praetorius M, Baker K, Brough DE.

Otol Neurotol. 2007 Feb;28(2):223-31.

PMID:
17255891
32.

Novel adenovirus vaccine vectors based on the enteric-tropic serotype 41.

Lemiale F, Haddada H, Nabel GJ, Brough DE, King CR, Gall JG.

Vaccine. 2007 Mar 1;25(11):2074-84. Epub 2006 Nov 28.

33.

Pharmacodynamics of adenovector distribution within the inner ear tissues of the mouse.

Praetorius M, Baker K, Brough DE, Plinkert P, Staecker H.

Hear Res. 2007 May;227(1-2):53-8. Epub 2006 Nov 1.

PMID:
17081711
34.

Comprehensive characterization of the 293-ORF6 cell line.

Butman BT, Lizonova A, Brough DE, Sowers JM, Sheets R, Gall J, Newton P, Gomez P.

Dev Biol (Basel). 2006;123:225-33; discussion 265-6. No abstract available.

PMID:
16566448
35.

Repeated administration of adenovector in the eye results in efficient gene delivery.

Hamilton MM, Brough DE, McVey D, Bruder JT, King CR, Wei LL.

Invest Ophthalmol Vis Sci. 2006 Jan;47(1):299-305.

PMID:
16384977
36.

Auditory hair cell replacement and hearing improvement by Atoh1 gene therapy in deaf mammals.

Izumikawa M, Minoda R, Kawamoto K, Abrashkin KA, Swiderski DL, Dolan DF, Brough DE, Raphael Y.

Nat Med. 2005 Mar;11(3):271-6. Epub 2005 Feb 13.

PMID:
15711559
37.

Drug delivery to the inner ear using gene therapy.

Staecker H, Brough DE, Praetorius M, Baker K.

Otolaryngol Clin North Am. 2004 Oct;37(5):1091-108. Review.

PMID:
15474113
38.

Adenovirus vector library: an approach to the discovery of gene and protein function.

McVey D, Zuber M, Brough DE, Kovesdi I.

J Gen Virol. 2003 Dec;84(Pt 12):3417-22.

PMID:
14645922
39.

Math1 gene transfer generates new cochlear hair cells in mature guinea pigs in vivo.

Kawamoto K, Ishimoto S, Minoda R, Brough DE, Raphael Y.

J Neurosci. 2003 Jun 1;23(11):4395-400.

40.

Local adenoviral-mediated inducible nitric oxide synthase gene transfer inhibits neointimal formation in the porcine coronary stented model.

Wang K, Kessler PD, Zhou Z, Penn MS, Forudi F, Zhou X, Tarakji K, Kibbe M, Kovesdi I, Brough DE, Topol EJ, Lincoff AM.

Mol Ther. 2003 May;7(5 Pt 1):597-603.

41.

Rapid construction of adenoviral vectors by lambda phage genetics.

McVey D, Zuber M, Ettyreddy D, Brough DE, Kovesdi I.

J Virol. 2002 Apr;76(8):3670-7.

42.

Pigment epithelium-derived factor inhibits retinal and choroidal neovascularization.

Mori K, Duh E, Gehlbach P, Ando A, Takahashi K, Pearlman J, Mori K, Yang HS, Zack DJ, Ettyreddy D, Brough DE, Wei LL, Campochiaro PA.

J Cell Physiol. 2001 Aug;188(2):253-63.

PMID:
11424092
44.

Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen.

Kurihara T, Brough DE, Kovesdi I, Kufe DW.

J Clin Invest. 2000 Sep;106(6):763-71.

45.

Improved production of adenovirus vectors expressing apoptotic transgenes.

Bruder JT, Appiah A, Kirkman WM 3rd, Chen P, Tian J, Reddy D, Brough DE, Lizonova A, Kovesdi I.

Hum Gene Ther. 2000 Jan 1;11(1):139-49.

PMID:
10646646
46.

Construction of a pseudoreceptor that mediates transduction by adenoviruses expressing a ligand in fiber or penton base.

Einfeld DA, Brough DE, Roelvink PW, Kovesdi I, Wickham TJ.

J Virol. 1999 Nov;73(11):9130-6.

47.
48.

The coxsackievirus-adenovirus receptor protein can function as a cellular attachment protein for adenovirus serotypes from subgroups A, C, D, E, and F.

Roelvink PW, Lizonova A, Lee JG, Li Y, Bergelson JM, Finberg RW, Brough DE, Kovesdi I, Wickham TJ.

J Virol. 1998 Oct;72(10):7909-15.

49.
50.

Adenoviral vectors for gene transfer.

Kovesdi I, Brough DE, Bruder JT, Wickham TJ.

Curr Opin Biotechnol. 1997 Oct;8(5):583-9. Review.

PMID:
9353227

Supplemental Content

Loading ...
Support Center